Mountain Crest Acquisition Corp. V Receives Nasdaq Deficiency Notice

Biotechnology
Biotechnology
Listing Rules
Listing Rules
Merger Vote:
Nov 11, 2026
Industry:
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Market Cap.:
38.13 m.

Show Chart?

Load external content from TradingView!

*You can change or withdraw your consent at any time in the footer under Cookies.

Mountain Crest Acquisition Corp. V Faces Nasdaq Listing Deficiency Due to Delayed Filings

New York, New York July 24, 2024 Mountain Crest Acquisition Corp. V (NASDAQ: MCAG) announced it has received a deficiency notification letter from The Nasdaq Stock Market LLC.

... Read on — Members only

About Cubebio Co., Ltd

CUBEBIO is an in-vitro diagnostic company that has developed a technology that can distinguish the presence of cancer in the body at an early stage by analyzing the concentration of specific metabolites in urine using urine that can be easily collected, with a focus on increasing the accessibility of cancer screening. CUBEBIO holds 37 Korean patents related to cancer diagnosis, based on which it has developed CEED-PG/PGS in addition to the pancreatic cancer diagnostic kit CEED-NOVUS-P and the multi-cancer detection kit CEED-NOVUS. Recently, through a KRW 20 billion or approximately $14.5 million contract with Taiwan Biotech Co., Ltd. to supply cancer screening products, CUBEBIO will exclusively supply its products to Taiwan, Vietnam, and Malaysia (the “Taiwan Biotech Contract”). CUBEBIO does not expect to generate revenues under the Taiwan Biotech Contract until CUBEBIO’s products are approved for sale in Taiwan, Vietnam, and Malaysia which may take up to 24 months or more. CUBEBIO is in the process of working on agreements to supply its cancer screening products in the United States and Japan.

View Company Details

More MCAG News

Continue exploring

SPACSTAR Tools

Scroll to Top